Indication: Thymoglobulin® (anti-thymocyte globulin (rabbit)) is indicated for the prophylaxis and treatment of acute rejection in patients receiving a kidney transplant. Thymoglobulin is to be used in conjunction with concomitant immunosuppression.
Indication: Thymoglobulin® (anti-thymocyte globulin (rabbit)) is indicated for the prophylaxis and treatment of acute rejection in patients receiving a kidney transplant. Thymoglobulin is to be used in conjunction with concomitant immunosuppression.
For kidney transplant immunosuppression: Protection in a hostile environment
Thymoglobulin® is the only T-cell-depleting agent that is FDA approved for prophylaxis of acute rejection.1,2

Multiple Risk factors should be considered when evaluating the risk for acute rejection.3,4

Thymoglobulin may induce immunosuppression through multiple pathways.1

Learn more about clinical trial data supporting the use of Thymoglobulin.

The approved dose of Thymoglobulin offers clinically demonstrated protection for your patient's new kidney.1

Important Safety Information

WARNING: IMMUNOSUPPRESSION. Thymoglobulin should only be used by physicians experienced in immunosuppressive therapy in transplantation.

Important Safety Information

WARNING: IMMUNOSUPPRESSION. Thymoglobulin should only be used by physicians experienced in immunosuppressive therapy in transplantation.

Click here for full Prescribing Information including Boxed WARNING.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

References:
  1. Thymoglobulin [prescribing information]. Cambridge, MA: Genzyme Corporation; 2020.
  2. Atgam [prescribing information]. New York, NY: Pfizer, Inc.; 2018.
  3. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2013 Annual Data Report: kidney. Am J Transplant. 2015;15(suppl 2):1-34.
  4. Hart A, Smith JM, Skeans MA, et al. Kidney. Am J Transplant. 2016;16(suppl 2):11-46.

Footnotes:

*Approved for treatment of acute rejection in patients receiving a kidney transplant 1998. Approved for prophylaxis of acute rejection in patients receiving a kidney transplant 2017. Thymoglobulin is to be used in conjunction with concomitant immunosuppression.